Item in Clipboard
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort StudyChristopher D Jensen et al. Ann Intern Med. 2016.
. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26. Authors Christopher D Jensen, Douglas A Corley, Virginia P Quinn, Chyke A Doubeni, Ann G Zauber, Jeffrey K Lee, Wei K Zhao, Amy R Marks, Joanne E Schottinger, Nirupa R Ghai, Alexander T Lee, Richard Contreras, Carrie N Klabunde, Charles P Quesenberry, Theodore R Levin, Pauline A MysliwiecItem in Clipboard
AbstractBackground: The fecal immunochemical test (FIT) is a common method for colorectal cancer (CRC) screening, yet its acceptability and performance over several rounds of annual testing are largely unknown.
Objective: To assess FIT performance characteristics over 4 rounds of annual screening.
Design: Retrospective cohort study.
Setting: Kaiser Permanente Northern and Southern California.
Patients: 323 349 health plan members aged 50 to 70 years on their FIT mailing date in 2007 or 2008 who completed the first round of FIT and were followed for up to 4 screening rounds.
Measurements: Screening participation, FIT positivity (≥20 µg of hemoglobin/g), positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
Results: Of the patients invited for screening, 48.2% participated in round 1. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of round 1 participants crossed over to endoscopy over 4 screening rounds-7.0% due to a positive FIT result. The FIT positivity rate (5.0%) and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in round 1. Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within 1 year of testing, including 84.5% in round 1 and 73.4% to 78.0% in subsequent rounds.
Limitation: Screening detection, rather than long-term cancer prevention, was evaluated.
Conclusion: Annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening.
Primary funding source: National Institutes of Health.
Conflict of interest statementDisclosures : Drs. Jensen, Corley, Quesenberry, and Levin report grant support from the National Cancer Institute during the conduct of the study. Dr. Quinn reports grant support from the National Institutes of Health during the conduct of the study. Dr. Doubeni reports compensation for 1-time consultancy (Exact Sciences) outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0983 .
FiguresAppendix Figure. Pattern of FIT performance measures…
Appendix Figure. Pattern of FIT performance measures over 4 rounds of annual screening*
CRC =…
Appendix Figure. Pattern of FIT performance measures over 4 rounds of annual screening*CRC = colorectal cancer; FIT = fecal immunochemical testing; PPV = positive predictive value. *See Tables 2 and 3 for numerators, denominators, and percentages. †Data available for Kaiser Permanente Northern California only. ‡Advanced adenoma defined as adenomas with villous or tubulovillous histology.
Figure. Study flow diagram.*
The figure includes…
Figure. Study flow diagram.*
The figure includes 1192 patients with CRC who were screened by…
Figure. Study flow diagram.*The figure includes 1192 patients with CRC who were screened by FIT the year before diagnosis. Further, there were 118 additional patients with CRC diagnosed more than 1 y beyond the FIT screening date and 101 additional patients diagnosed with CRC who either crossed over to endoscopy in subsequent rounds or terminated health plan membership but then rejoined. CRC = colorectal cancer; FIT = fecal immunochemical test. *Shading indicates where patients were censored or became ineligible for subsequent FIT screening. †Patients were eligible for the initial FIT mailing if they were aged 50 to 70 y and had ≥1 y of membership. See Methods section for exclusions. ‡Number censored because of CRC and includes patients with CRC diagnosed within 1 y after their FIT result.
Similar articlesvan der Vlugt M, Grobbee EJ, Bossuyt PMM, Bos A, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MCW, Dekker E. van der Vlugt M, et al. Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
Zorzi M, Hassan C, Capodaglio G, Fedato C, Montaguti A, Turrin A, Rosano A, Monetti D, Stocco C, Baracco S, Russo F, Repici A, Rugge M. Zorzi M, et al. Gut. 2018 Dec;67(12):2124-2130. doi: 10.1136/gutjnl-2017-314753. Epub 2017 Nov 3. Gut. 2018. PMID: 29101260
Atkin W, Cross AJ, Kralj-Hans I, MacRae E, Piggott C, Pearson S, Wooldrage K, Brown J, Lucas F, Prendergast A, Marchevsky N, Patel B, Pack K, Howe R, Skrobanski H, Kerrison R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran S. Atkin W, et al. Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010. Health Technol Assess. 2019. PMID: 30618357 Free PMC article. Clinical Trial.
Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Tinmouth J, et al. Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
Quintero E. Quintero E. Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Gastroenterol Hepatol. 2009. PMID: 19577340 Review. Spanish.
Issaka RB, Singh MH, Oshima SM, Laleau VJ, Rachocki CD, Chen EH, Day LW, Sarkar U, Somsouk M. Issaka RB, et al. Am J Gastroenterol. 2017 Feb;112(2):375-382. doi: 10.1038/ajg.2016.555. Epub 2016 Dec 13. Am J Gastroenterol. 2017. PMID: 28154400 Free PMC article.
Levin TR, Jensen CD, Chawla NM, Sakoda LC, Lee JK, Zhao WK, Landau MA, Herm A, Eby E, Quesenberry CP, Corley DA. Levin TR, et al. Gastroenterology. 2020 Nov;159(5):1695-1704.e1. doi: 10.1053/j.gastro.2020.07.011. Epub 2020 Jul 20. Gastroenterology. 2020. PMID: 32702368 Free PMC article.
Dulskas A, Poskus T, Kildusiene I, Patasius A, Stulpinas R, Laurinavičius A, Mašalaitė L, Milaknytė G, Stundienė I, Venceviciene L, Strupas K, Samalavicius NE, Smailyte G. Dulskas A, et al. Cancers (Basel). 2021 Mar 6;13(5):1129. doi: 10.3390/cancers13051129. Cancers (Basel). 2021. PMID: 33800772 Free PMC article.
Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Robertson DJ, et al. Am J Gastroenterol. 2017 Jan;112(1):37-53. doi: 10.1038/ajg.2016.492. Epub 2016 Oct 18. Am J Gastroenterol. 2017. PMID: 27753435 Review.
Berger BM, Levin B, Hilsden RJ. Berger BM, et al. World J Gastrointest Oncol. 2016 May 15;8(5):450-8. doi: 10.4251/wjgo.v8.i5.450. World J Gastrointest Oncol. 2016. PMID: 27190584 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3